Published in BMJ on January 26, 2009
Elite Controller and ART-treated HIV+ Statin Versus ASA Treatment Intervention Study | NCT02081638
The end of AIDS: HIV infection as a chronic disease. Lancet (2013) 3.96
Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis (2010) 3.79
HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med (2010) 3.00
HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr (2012) 2.95
Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis (2013) 2.82
The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood (2013) 2.72
Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis (2012) 2.45
Frailty as a novel predictor of mortality and hospitalization in individuals of all ages undergoing hemodialysis. J Am Geriatr Soc (2013) 2.06
Untreated HIV: harmful even at high CD4 cell counts. Lancet (2010) 2.01
Immunologic basis of cardiovascular disease in HIV-infected adults. J Infect Dis (2012) 1.91
Biomarkers of immune dysfunction in HIV. Curr Opin HIV AIDS (2010) 1.83
Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals. JAMA Intern Med (2015) 1.65
An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS (2013) 1.64
Baseline kidney function as predictor of mortality and kidney disease progression in HIV-positive patients. Am J Kidney Dis (2012) 1.62
The lifetime medical cost savings from preventing HIV in the United States. Med Care (2015) 1.61
Targeting of mTOR catalytic site inhibits multiple steps of the HIV-1 lifecycle and suppresses HIV-1 viremia in humanized mice. Proc Natl Acad Sci U S A (2015) 1.59
Early immune senescence in HIV disease. Curr HIV/AIDS Rep (2010) 1.58
Co-morbidities in persons infected with HIV: increased burden with older age and negative effects on health-related quality of life. AIDS Patient Care STDS (2013) 1.51
Age in antiretroviral therapy programmes in South Africa: a retrospective, multicentre, observational cohort study. Lancet HIV (2015) 1.47
Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLoS One (2011) 1.42
HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy. AIDS (2009) 1.41
Evidence for innate immune system activation in HIV type 1-infected elite controllers. J Infect Dis (2013) 1.36
Is HIV a model of accelerated or accentuated aging? J Gerontol A Biol Sci Med Sci (2013) 1.33
HIV infection and older Americans: the public health perspective. Am J Public Health (2012) 1.31
The next therapeutic challenge in HIV: polypharmacy. Drugs Aging (2013) 1.30
Projected Lifetime Healthcare Costs Associated with HIV Infection. PLoS One (2015) 1.24
The dual impact of HIV-1 infection and aging on naïve CD4 T-cells: additive and distinct patterns of impairment. PLoS One (2011) 1.23
Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. AIDS (2010) 1.23
Finding a cure for HIV: will it ever be achievable? J Int AIDS Soc (2011) 1.18
Neurocognitive effects of HIV, hepatitis C, and substance use history. J Int Neuropsychol Soc (2011) 1.15
Growing older with HIV/AIDS: new public health challenges. Am J Public Health (2013) 1.15
Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS One (2010) 1.13
Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials. Hum Vaccin Immunother (2013) 1.12
HIV-Associated Venous Thromboembolism. Mediterr J Hematol Infect Dis (2011) 1.11
Immune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs. Immunol Rev (2013) 1.08
Highly significant antiviral activity of HIV-1 LTR-specific tre-recombinase in humanized mice. PLoS Pathog (2013) 1.08
Immune activation and collateral damage in AIDS pathogenesis. Front Immunol (2013) 1.08
HIV-associated lung infections and complications in the era of combination antiretroviral therapy. Proc Am Thorac Soc (2011) 1.05
Th17, gut, and HIV: therapeutic implications. Curr Opin HIV AIDS (2010) 1.05
The veterans aging cohort study index is associated with concurrent risk for neurocognitive impairment. J Acquir Immune Defic Syndr (2014) 1.03
Association between peripheral T-Lymphocyte activation and impaired bone mineral density in HIV-infected patients. J Transl Med (2013) 1.03
HIV/AIDS, comorbidity, and alcohol: can we make a difference? Alcohol Res Health (2010) 1.02
Premature and accelerated aging: HIV or HAART? Front Genet (2013) 1.01
Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis. Oncology (2011) 0.99
Gut epithelial barrier and systemic inflammation during chronic HIV infection. AIDS (2015) 0.99
Premature decline of serum total testosterone in HIV-infected men in the HAART-era. PLoS One (2011) 0.98
HIV-1 infection induces strong production of IP-10 through TLR7/9-dependent pathways. AIDS (2013) 0.97
Increased coronary vessel wall thickness in HIV-infected young adults. Clin Infect Dis (2014) 0.97
When to start antiretroviral therapy. Curr HIV/AIDS Rep (2010) 0.97
Cost of noninfectious comorbidities in patients with HIV. Clinicoecon Outcomes Res (2013) 0.96
Human immunodeficiency virus (HIV) latency: the major hurdle in HIV eradication. Mol Med (2012) 0.96
Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patients. Curr Opin HIV AIDS (2014) 0.96
Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study. PLoS One (2012) 0.95
Achieving a cure for HIV infection: do we have reasons to be optimistic? J Antimicrob Chemother (2012) 0.95
"Working together to reach a goal": MSM's perceptions of dyadic HIV care for same-sex male couples. J Acquir Immune Defic Syndr (2013) 0.93
Persistently elevated serum interleukin-6 predicts mortality among adults receiving combination antiretroviral therapy in Botswana: results from a clinical trial. AIDS Res Hum Retroviruses (2013) 0.93
Monocytes expand with immune dysregulation and is associated with insulin resistance in older individuals with chronic HIV. PLoS One (2014) 0.92
Immune aging, dysmetabolism, and inflammation in neurological diseases. Front Neurosci (2015) 0.92
The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial. PLoS One (2014) 0.92
Ageing and long-term CD4 cell count trends in HIV-positive patients with 5 years or more combination antiretroviral therapy experience. HIV Med (2012) 0.92
Level of adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy (HAART). AIDS Behav (2015) 0.91
An active lifestyle is associated with better neurocognitive functioning in adults living with HIV infection. J Neurovirol (2014) 0.91
mRNA transfection of a novel TAL effector nuclease (TALEN) facilitates efficient knockout of HIV co-receptor CCR5. Nucleic Acids Res (2015) 0.91
Cerebrospinal fluid metabolomics reveals altered waste clearance and accelerated aging in HIV patients with neurocognitive impairment. AIDS (2014) 0.90
HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial. Retrovirology (2015) 0.89
HIV testing trends: Southeastern Pennsylvania, 2002-2010. AIDS Patient Care STDS (2014) 0.88
Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES. AIDS Res Hum Retroviruses (2012) 0.88
Clinical utility of biomarkers of endothelial activation and coagulation for prognosis in HIV infection: a systematic review. Virulence (2013) 0.87
HIV and proteinuria in an injection drug user population. Clin J Am Soc Nephrol (2010) 0.87
Can HIV-1-Specific ADCC Assist the Clearance of Reactivated Latently Infected Cells? Front Immunol (2015) 0.87
HIV and aging: insights from the Asia Pacific HIV Observational Database (APHOD). HIV Med (2014) 0.86
Risk of deaths, AIDS-defining and non-AIDS defining events among Ghanaians on long-term combination antiretroviral therapy. PLoS One (2014) 0.86
Cardiac effects of in-utero exposure to antiretroviral therapy in HIV-uninfected children born to HIV-infected mothers. AIDS (2015) 0.86
HIV RNA levels in plasma and cervical-vaginal lavage fluid in elite controllers and HAART recipients. AIDS (2014) 0.86
Galectin-9 is rapidly released during acute HIV-1 infection and remains sustained at high levels despite viral suppression even in elite controllers. AIDS Res Hum Retroviruses (2014) 0.85
Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population. Open Forum Infect Dis (2015) 0.84
Association of the veterans aging cohort study index with exercise capacity in HIV-infected adults. AIDS Res Hum Retroviruses (2013) 0.84
Absolute leukocyte telomere length in HIV-infected and uninfected individuals: evidence of accelerated cell senescence in HIV-associated chronic obstructive pulmonary disease. PLoS One (2015) 0.83
Impact of HMGB1/TLR Ligand Complexes on HIV-1 Replication: Possible Role for Flagellin during HIV-1 Infection. Int J Microbiol (2012) 0.83
A challenge for the future: aging and HIV infection. Immunol Res (2010) 0.83
Progressive proximal-to-distal reduction in expression of the tight junction complex in colonic epithelium of virally-suppressed HIV+ individuals. PLoS Pathog (2014) 0.83
Human endogenous retrovirus expression is inversely associated with chronic immune activation in HIV-1 infection. PLoS One (2012) 0.83
Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy. Crit Rev Immunol (2013) 0.83
Sex disparities in overall burden of disease among HIV-infected individuals in the Veterans Affairs healthcare system. J Gen Intern Med (2013) 0.83
Reasons for limiting drinking in an HIV primary care sample. Alcohol Clin Exp Res (2014) 0.83
Definition of advanced age in HIV infection: looking for an age cut-off. AIDS Res Hum Retroviruses (2012) 0.82
New insights into immune reconstitution inflammatory syndrome of the central nervous system. Curr Opin HIV AIDS (2014) 0.82
Corneal endothelial cells provide evidence of accelerated cellular senescence associated with HIV infection: a case-control study. PLoS One (2013) 0.82
Impact of age on markers of HIV-1 disease. Future Virol (2013) 0.82
Taming HIV-related inflammation with physical activity: a matter of timing. AIDS Res Hum Retroviruses (2014) 0.81
Effects of human immunodeficiency virus and metabolic complications on myocardial nutrient metabolism, blood flow, and oxygen consumption: a cross-sectional analysis. Cardiovasc Diabetol (2011) 0.81
Using community health workers to improve clinical outcomes among people living with HIV: a randomized controlled trial. AIDS Behav (2013) 0.81
HIV infection and glycemic response to newly initiated diabetic medical therapy. AIDS (2012) 0.81
Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus. Vasc Health Risk Manag (2015) 0.81
Study design issues in evaluating immune biomarkers. Curr Opin HIV AIDS (2013) 0.80
Diabetes and Hypertension among Patients Receiving Antiretroviral Treatment Since 1998 in Senegal: Prevalence and Associated Factors. ISRN AIDS (2012) 0.80
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med (2015) 15.06
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01
Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med (2003) 12.23
Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med (2006) 9.21
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet (2008) 8.73
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis (2008) 6.73
Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS (2003) 5.61
Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis (2005) 5.20
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet (2006) 5.00
HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med (2012) 4.08
Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet (2004) 3.59
The role of HIV in serious diseases other than AIDS. AIDS (2008) 3.39
Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis (2008) 3.35
Projected life expectancy of people with HIV according to timing of diagnosis. AIDS (2012) 3.09
A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. J Infect Dis (2002) 2.87
Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS (2010) 2.85
Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS (2004) 2.76
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS (2005) 2.45
HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS (2008) 2.27
Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis (2009) 2.20
HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol (2010) 2.06
Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther (2008) 1.83
Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis (2005) 1.80
Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol (2002) 1.79
Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis (2012) 1.76
Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS (2002) 1.74
Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers. AIDS (2006) 1.71
Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis (2004) 1.70
Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. Arch Intern Med (2006) 1.69
Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS (2002) 1.63
When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies. AIDS (2003) 1.60
Late diagnosis in the HAART era: proposed common definitions and associations with mortality. AIDS (2010) 1.57
Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS (2005) 1.52
Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. AIDS (2006) 1.52
Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS (2007) 1.51
Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr (2003) 1.44
Decline in esophageal candidiasis and use of antimycotics in European patients with HIV. Am J Gastroenterol (2005) 1.42
The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study. Cancer (2004) 1.39
Virological rebound after suppression on highly active antiretroviral therapy. AIDS (2003) 1.34
Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. J Infect Dis (2010) 1.33
Regional changes over time in initial virologic response rates to combination antiretroviral therapy across Europe. J Acquir Immune Defic Syndr (2006) 1.27
Factors associated with adherence amongst 5295 people receiving antiretroviral therapy as part of an international trial. J Infect Dis (2012) 1.25
Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2009) 1.23
Gender and clinical outcomes after starting highly active antiretroviral treatment: a cohort study. J Acquir Immune Defic Syndr (2002) 1.22
Should HIV therapy be started at a CD4 cell count above 350 cells/microl in asymptomatic HIV-1-infected patients? Curr Opin Infect Dis (2009) 1.21
Does ART prevent HIV transmission among MSM? AIDS (2012) 1.20
Physical and psychological symptoms and risk of virologic rebound among patients with virologic suppression on antiretroviral therapy. J Acquir Immune Defic Syndr (2010) 1.20
Long-term trends in adherence to antiretroviral therapy from start of HAART. AIDS (2010) 1.17
Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen. AIDS (2005) 1.16
Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study. J Infect Dis (2002) 1.15
Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score. AIDS (2007) 1.15
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Arch Intern Med (2010) 1.12
Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study. AIDS (2008) 1.11
The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy. AIDS (2003) 1.09
Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention? AIDS (2009) 1.09
Changes over time in post-seroconversion CD4 cell counts in the Italian HIV-Seroconversion Study: 1985-2002. AIDS (2005) 1.07
The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors. AIDS (2007) 1.07
Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression? AIDS (2008) 1.07
CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK. Haematologica (2009) 1.07
Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004. Arch Intern Med (2007) 1.06
'Test-and-treat': the end of the HIV epidemic? Curr Opin Infect Dis (2011) 1.06
Changes in viral load in people with virological failure who remain on the same HAART regimen. Antivir Ther (2003) 1.04
Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy. Antivir Ther (2005) 1.03
Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. Clin Infect Dis (2007) 1.02
Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure? AIDS (2002) 1.02
Stability of antiretroviral regimens in patients with viral suppression. AIDS (2008) 1.00
Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. AIDS (2008) 0.99
Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events. AIDS (2013) 0.98
Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring. PLoS One (2012) 0.98
Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy. AIDS (2004) 0.96
The 'Antiretrovirals, Sexual Transmission Risk and Attitudes' (ASTRA) study. Design, methods and participant characteristics. PLoS One (2013) 0.96
HIV-1 subtypes and response to combination antiretroviral therapy in Europe. Antivir Ther (2006) 0.96
A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men. Int J Epidemiol (2007) 0.96
Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: evidence from the I.Co.N.A. Study. J Acquir Immune Defic Syndr (2003) 0.95
Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts. Antivir Ther (2007) 0.95
Associations between immune depression and cardiovascular events in HIV infection. AIDS (2013) 0.94
Effect of transient antiretroviral treatment during acute HIV infection: comparison of the Quest trial results with CASCADE natural history study. Antivir Ther (2007) 0.94
Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts. J Infect Dis (2002) 0.93
Markers of HIV-1 disease progression in individuals with haemophilia coinfected with hepatitis C virus: a longitudinal study. Lancet (2002) 0.93
Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures. AIDS (2007) 0.91
A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial. Antivir Ther (2006) 0.90
Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study. J Acquir Immune Defic Syndr (2008) 0.89
Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study. Antivir Ther (2004) 0.89
Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapy. J Acquir Immune Defic Syndr (2010) 0.89
HIV survival benefit associated with earlier antiviral therapy. Ann Intern Med (2004) 0.88
Use of viral load measured after 4 weeks of highly active antiretroviral therapy to predict virologic outcome at 24 weeks for HIV-1-positive individuals. J Acquir Immune Defic Syndr (2004) 0.88
Modelling the impact of treatment with individual antiretrovirals. Curr Opin HIV AIDS (2011) 0.87
Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease. AIDS (2014) 0.87
Analysis of virological efficacy in trials of antiretroviral regimens: drawbacks of not including viral load measurements after premature discontinuation of therapy. Antivir Ther (2002) 0.87
Further research needed to support a policy of antiretroviral therapy as an HIV prevention initiative. Antivir Ther (2013) 0.87
CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. AIDS (2013) 0.86
Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy. Antivir Ther (2010) 0.86
Drug switching and virologic-based endpoints in trials of antiretroviral drugs for HIV infection. AIDS (2004) 0.85
Predicting the potential benefits of early initiation of ART: time to do a trial to find out. Curr Opin HIV AIDS (2009) 0.85
Insurability of HIV-positive people treated with antiretroviral therapy in Europe: collaborative analysis of HIV cohort studies. AIDS (2013) 0.84
Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C. Scand J Infect Dis (2006) 0.84